Cancer Epigenetics Laboratory
The Cancer Epigenetics Laboratory is focused on understanding the molecular determinants of tumor cell metastatic progression and drug resistance in cancer, particularly in aggressive forms of breast tumors and distant metastases.
Goals and Areas of Research
Our group focuses on the epigenetic and epi-transcriptomic mechanisms that regulate gene expression programs in different tumor states, both at a regional level and in long-range chromatin interactions. To investigate these regulatory networks we utilize a variety of analytical strategies including tumor tissue microdissection, CRISPR-guided genome and epigenome editing, drug-based transcriptional reprogramming, transcriptomic and epigenomic profiling, aberrant splicing modulation, and mathematical modeling. By exploring these novel concepts in cancer research, our main goals include the characterization, validation, and implementation of novel cancer molecular alterations with potential to improve the current clinical standard of care on diagnostic, prognostic and therapeutic approaches.
The Cancer Epigenetics Laboratory has been made possible thanks to the Saint John’s Cancer Institute Translational Research Fund.
Funding: The Cancer Epigenetics Laboratory is also supported by the Associates for Breast and Prostate Cancer Studies (ABCs) foundation and the Fashion Footwear Association of New York (FFANY) foundation.
Partnership & Collaboration
The Cancer Epigenetics Laboratory holds several collaborative studies with Saint John’s Cancer Institute faculty members and several external researchers from different institutions.Learn More
Current Research Topics
Our Cancer Epigenetics Laboratory focuses on understanding the molecular determinants of metastatic progression and drug resistance modelling in cancer, particularly in different subtypes of breast neoplasm and distant metastases.Learn More
Meet Our Team
The Cancer Epigenetics team is committed to finding novel treatment options for tumor cell metastatic progression and drug resistance in cancer.Meet Our Team